Monte Rosa Therapeutics (GLUE) EBT Margin (2024 - 2026)
Monte Rosa Therapeutics' (GLUE) quarterly EBT Margin came in at 1033.74% in Q1 2026, down 108992.0% year-on-year from N/an in Q1 2025, and up 2.32% quarter-over-quarter from 1058.25% in Q4 2025.
Monte Rosa Therapeutics (GLUE) EBT Margin (2024 - 2026) Analysis & Trends
Monte Rosa Therapeutics' EBT Margin history runs 3 years deep, the most recent figure standing at 1033.74% for Q1 2026.
- On a quarterly basis, EBT Margin fell 108992.0% year-over-year to 1033.74% in Q1 2026; TTM through Mar 2026 was 2679.88%, a 268582.0% decrease from a year earlier, with the FY2025 full-year figure at 18.66%, up 7408.0% from the prior year.
- EBT Margin rose to 1033.74% in Q1 2026 per GLUE's latest filing, from 1058.25% in the prior quarter.
- Across five years, EBT Margin topped out at 56.17% in Q1 2025 and bottomed at 2996.71% in Q1 2024.
- The 3-year median for EBT Margin is 258.12% (2024), against an average of 659.25%.
- Across the five-year window, EBT Margin surged 305288 bps in 2025 and slumped 108992 bps in 2026, its largest moves.
- Year by year, EBT Margin stood at 25.72% in 2024, then tumbled by 4214 bps to 1058.25% in 2025, then increased by 2 bps to 1033.74% in 2026.
- Per Business Quant, the three latest GLUE EBT Margin figures stand at 1033.74% (Q1 2026), 1058.25% (Q4 2025), and 20.17% (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 17.13% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 41.95% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 23.05% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 34.77% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Monte Rosa Therapeutics | 2.30 Bn | 1.62 Bn | - | -1,033.74% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1,033.74% |
| Dec 31, 2025 | -1,058.25% |
| Sep 30, 2025 | -20.17% |
| Jun 30, 2025 | -7.91% |
| Mar 31, 2025 | 56.17% |
| Dec 31, 2024 | 25.72% |
| Sep 30, 2024 | -258.12% |
| Jun 30, 2024 | -640.21% |
| Mar 31, 2024 | -2,996.71% |